Researchers are advancing Rare disease biomarker discovery to unlock targeted therapies, earlier diagnosis, and better patient stratification in small patient populations.
Progress here depends on collaboration, open data, and robust validation across independent cohorts, with meaningful gains for care that can scale beyond rare conditions.